Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Enanta Pharmaceuticals Inc (NASDAQ: ENTA) closed at $11.30 in the last session, down -0.79% from day before closing price of $11.39. In other words, the price has decreased by -$0.79 from its previous closing price. On the day, 0.54 million shares were traded. ENTA stock price reached its highest trading level at $11.69 during the session, while it also had its lowest trading level at $11.22.
Ratios:
We take a closer look at ENTA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.92 and its Current Ratio is at 4.92. In the meantime, Its Debt-to-Equity ratio is 1.52 whereas as Long-Term Debt/Eq ratio is at 1.29.
On August 08, 2023, Jefferies Downgraded its rating to Hold which previously was Buy and also lowered its target price recommendation from $49 to $18.
On December 09, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $56.H.C. Wainwright initiated its Buy rating on December 09, 2022, with a $56 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jul 15 ’24 when Rottinghaus Scott T. sold 5,375 shares for $17.08 per share. The transaction valued at 91,805 led to the insider holds 21,717 shares of the business.
Rottinghaus Scott T. sold 4,299 shares of ENTA for $64,786 on Jul 11 ’24. The Chief Medical Officer now owns 23,988 shares after completing the transaction at $15.07 per share. On Jul 12 ’24, another insider, Rottinghaus Scott T., who serves as the Chief Medical Officer of the company, sold 2,271 shares for $15.04 each. As a result, the insider received 34,156 and left with 21,717 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ENTA now has a Market Capitalization of 241337488 and an Enterprise Value of 235519856. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.33 while its Price-to-Book (P/B) ratio in mrq is 1.61. Its current Enterprise Value per Revenue stands at 3.273 whereas that against EBITDA is -1.957.
Stock Price History:
Over the past 52 weeks, ENTA has reached a high of $17.80, while it has fallen to a 52-week low of $8.08. The 50-Day Moving Average of the stock is -15.63%, while the 200-Day Moving Average is calculated to be -12.93%.
Shares Statistics:
According to the various share statistics, ENTA traded on average about 165.25K shares per day over the past 3-months and 155820 shares per day over the past 10 days. A total of 21.06M shares are outstanding, with a floating share count of 19.70M. Insiders hold about 7.02% of the company’s shares, while institutions hold 104.00% stake in the company. Shares short for ENTA as of 1724976000 were 2910550 with a Short Ratio of 17.61, compared to 1722384000 on 2800039. Therefore, it implies a Short% of Shares Outstanding of 2910550 and a Short% of Float of 14.610000000000001.
